Skip to content

Study · Non-randomized trial · n = 27 · 2003

8 results

[The effect of cerebrolysin on cognitive functions in childhood autism and in Asperger syndrome].

Krasnoperova MG, Bashina VM, Skvortsov IA, Simashkova NV

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2003Cited by 2 (Europe PMC)

PMID12872620 (opens in a new tab)PepBankPUB-12872620
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with autism or Asperger's syndrome, Cerebrolysin improved expressive speech.

    In plain wordsIn children with autism or Asperger's syndrome, Cerebrolysin improved expressive speech after treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseExpressive speech
    Study

    n = 27

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 microinjections of 0.1 ml daily · intramuscularly and perinervously · 5 daysAs given in this study (human).

    Source sentences

    Summary
    CL therapy resulted in improvement of cognitive functions (expressive and receptive speech, fine motoring, playing).
    2 context sentences
    Summary · context
    Nineteen children with childhood autism and 8 with Asperger's syndrome aged 2-8 year, were treated with cerebrolysin (CL) in inpatient clinic.
    Summary · context
    All the patients received 10 microinjections (intramuscularly and perinervously) of 0.1 ml CL daily during 5 days.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with autism or Asperger's syndrome, Cerebrolysin improved receptive speech.

    In plain wordsIn children with autism or Asperger's syndrome, Cerebrolysin improved receptive speech after treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseReceptive speech
    Study

    n = 27

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 microinjections of 0.1 ml daily · intramuscularly and perinervously · 5 daysAs given in this study (human).

    Source sentences

    Summary
    CL therapy resulted in improvement of cognitive functions (expressive and receptive speech, fine motoring, playing).
    2 context sentences
    Summary · context
    Nineteen children with childhood autism and 8 with Asperger's syndrome aged 2-8 year, were treated with cerebrolysin (CL) in inpatient clinic.
    Summary · context
    All the patients received 10 microinjections (intramuscularly and perinervously) of 0.1 ml CL daily during 5 days.
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with autism or Asperger's syndrome, Cerebrolysin improved fine motoring.

    In plain wordsIn children with autism or Asperger's syndrome, Cerebrolysin improved fine movement after treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFine motoring
    Study

    n = 27

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    0.1 ml · intramuscularly and perinervously · 5 daysAs given in this study (human).

    Source sentences

    Summary
    CL therapy resulted in improvement of cognitive functions (expressive and receptive speech, fine motoring, playing).
    2 context sentences
    Summary · context
    Nineteen children with childhood autism and 8 with Asperger's syndrome aged 2-8 year, were treated with cerebrolysin (CL) in inpatient clinic.
    Summary · context
    All the patients received 10 microinjections (intramuscularly and perinervously) of 0.1 ml CL daily during 5 days.
  4. 04HumanNon-randomized trialEfficacy outcome

    In children with autism or Asperger's syndrome, Cerebrolysin improved playing.

    In plain wordsIn children with autism or Asperger's syndrome, Cerebrolysin improved playing after treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePlaying
    Study

    n = 27

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    0.1 ml · intramuscularly and perinervously · 5 daysAs given in this study (human).

    Source sentences

    Summary
    CL therapy resulted in improvement of cognitive functions (expressive and receptive speech, fine motoring, playing).
    2 context sentences
    Summary · context
    Nineteen children with childhood autism and 8 with Asperger's syndrome aged 2-8 year, were treated with cerebrolysin (CL) in inpatient clinic.
    Summary · context
    All the patients received 10 microinjections (intramuscularly and perinervously) of 0.1 ml CL daily during 5 days.
  5. 05HumanNon-randomized trialSafety outcome

    No negative effects were found after Cerebrolysin treatment in children with autism or Asperger's syndrome.

    In plain wordsNo negative effects were found in children with autism or Asperger's syndrome after Cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedNegative effects
    Study

    n = 27

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.1 ml · intramuscularly and perinervously · 5 daysAs given in this study (human).

    Source sentences

    Summary
    Any negative effects were not found.
    2 context sentences
    Summary · context
    Nineteen children with childhood autism and 8 with Asperger's syndrome aged 2-8 year, were treated with cerebrolysin (CL) in inpatient clinic.
    Summary · context
    All the patients received 10 microinjections (intramuscularly and perinervously) of 0.1 ml CL daily during 5 days.
  6. 06HumanNon-randomized trialEfficacy outcome

    Cognitive development benefits after Cerebrolysin were greater in children with Asperger's syndrome than in children with autism.

    In plain wordsCerebrolysin benefits for cognitive development were greater in children with Asperger's syndrome than in children with autism.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCognitive development response by diagnosis
    Study

    n = 27

    Comparator
    Children with childhood autism
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    0.1 ml · intramuscularly and perinervously · 5 daysAs given in this study (human).

    Measurements

    P value for cognitive development response by diagnosis
    < 0.005
    Asperger's syndrome versus childhood autism after CL therapy

    Source sentences

    Summary
    With regard to cognitive functions development, therapeutic efficacy proved to be more pronounced in the patients with Asperger's syndrome as compared to childhood autistic group (p < 0.005).
    2 context sentences
    Summary · context
    Nineteen children with childhood autism and 8 with Asperger's syndrome aged 2-8 year, were treated with cerebrolysin (CL) in inpatient clinic.
    Summary · context
    All the patients received 10 microinjections (intramuscularly and perinervously) of 0.1 ml CL daily during 5 days.
  7. 07HumanNon-randomized trialEfficacy outcome

    Positive effects of Cerebrolysin occurred in 89% of treated children with childhood autism.

    In plain wordsPositive effects occurred in 89% of children with autism after Cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePositive response in childhood autism
    Study

    n = 19

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    0.1 ml · intramuscularly and perinervously · 5 daysAs given in this study (human).

    Measurements

    Positive response
    89%
    childhood autism

    Source sentences

    Summary
    Positive effects were revealed in all the patients with Asperger's syndrome and in 89% of the patients with childhood autism.
    2 context sentences
    Summary · context
    Nineteen children with childhood autism and 8 with Asperger's syndrome aged 2-8 year, were treated with cerebrolysin (CL) in inpatient clinic.
    Summary · context
    All the patients received 10 microinjections (intramuscularly and perinervously) of 0.1 ml CL daily during 5 days.
  8. 08HumanNon-randomized trialEfficacy outcome

    Positive effects of Cerebrolysin occurred in all treated children with Asperger's syndrome.

    In plain wordsAll treated children with Asperger's syndrome showed positive effects after Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePositive response in Asperger's syndrome
    Study

    n = 8

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    0.1 ml · intramuscularly and perinervously · 5 daysAs given in this study (human).

    Source sentences

    Summary
    Positive effects were revealed in all the patients with Asperger's syndrome and in 89% of the patients with childhood autism.
    2 context sentences
    Summary · context
    Nineteen children with childhood autism and 8 with Asperger's syndrome aged 2-8 year, were treated with cerebrolysin (CL) in inpatient clinic.
    Summary · context
    All the patients received 10 microinjections (intramuscularly and perinervously) of 0.1 ml CL daily during 5 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT04751136

the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome

Mansoura University Children Hospitaln = 6430 Sept 2016 to 30 Aug 2019

Down Syndrome

Trial pageClinicalTrials.govUpdated 11 Feb 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.